Sona Nanotech Inc. announced that it has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, " ENDOSCOPE With EMR OPTICAL FIBER and THERMAL SENSOR for PHOTOTHERMAL THERAPY". A prototype of Sona's medical laser was engineered in conjunction with Minnetronix Medical to apply non-thermal, 860 nanometer wavelength high intensity infrared laser light. The device has been designed for use with Sona's patented/patent pending biocompatible gold nanorods which efficiently convert the non-thermal light energy into heat.

The device has controls to regulate the intensity and duration of the light exposure and to permit a user to monitor and control the temperature generated in tissue. The device is currently being used for the Company's ongoing pre-clinical efficacy study of its Targeted Hyperthermia Therapy cancer treatment at Dalhousie University. The Company also recently met with a group of leading surgeons and payer representatives in the U.S as part of its second EXCITE International panel discussion.

That roundtable evaluation and discussion, together with its recent pre-submission meeting with the U.S. Food and Drug Administration ("FDA"), provided important feedback and guidance to the Company on the development and validation path for its Targeted Hyperthermia therapy cancer therapy.